Maura Gillison, MD PhD
Michael Samuels, MD,
Open to Accrual
Head and Neck [HN]
Head and Neck
I
No
To determine the recommended phase2 dose (RP2D) of M3814 (peposertib) when given in combination with IMRT.
Pathologically (histologically) proven diagnosis of HNSCCof the oral cavity, oropharynx, larynx, or hypopharynx prior to registration; patients with oropharynx cancer need p16 determination by immunohistochemistry. Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer must be stages T1-2N2 -3 or T3N1-3 or T4N0-3; p16-positive oropharynx cancer patients,stages T4N0-3 or T1-3N2-3.
42
NRG-HN008 SIV Training Recording
Data collection for this study will be done exclusively through iMedidata Rave. The Rave system can be accessed through the iMedidata portal at https://login.imedidata.com.
NRG-HN008 Co-Morbidity form is to be printed out and completed by the clinical staff on paper and uploaded in iMedidata Rave.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.